Willow Biosciences Inc., (OTC:CANSF) a frontrunner in biotech innovations for sustainable ingredient production, reported its financial and operational results Tuesday morning for the fourth quarter and fiscal year 2023.

The year marked a period of significant reorganization and growth, culminating in a record revenue of $1.2 million, a 43% increase from the previous year.

In 2020, Willow announced a breakthrough in biotechnology, successfully developing a scalable process for producing cannabigerol (CBG) with over 99% purity and no detectable THC, which positions Willow to capture a significant market opportunity in high-purity cannabinoids.

The company's innovation bore fruit with its corticosteroid manufacturing platform showing...